Literature DB >> 6440825

Correlation between plasma carbamazepine-10,11-epoxide concentration and drug side-effects in children with epilepsy.

J F Schoeman, A A Elyas, E M Brett, P T Lascelles.   

Abstract

Ninety children with epilepsy were treated with carbamazepine (CBZ) alone or with other anticonvulsant drugs. Side-effects were noted in 14 patients. When 25 patients treated with CBZ alone (group 1) were compared with 27 on CBZ and sodium valproate (group 2) and with 38 on CBZ and one or more other anticonvulsants (group 3), the incidence of side-effects was two in group 1 (of whom one patient had a toxic plasma level of CBZ), but 12 in groups 2 and 3 combined. In all but three of the 14 patients with side-effects, plasma levels of CBZ were within the 'therapeutic range'. A significant difference was found between the carbamazepine-10,11-epoxide (CBZ-10,11-EPOX) levels in plasma and CBZ-10,11-EPOX/CBZ ratio in patients with and without side-effects. For five patients on CBZ and other drugs, changes in treatment resulted in changes in side-effects, and also in CBZ-10,11-EPOX levels. Three of these patients showed an interaction between CBZ and sodium valproate, with a correlation between plasma CBZ-10,11-EPOX and side-effects when either drug was introduced or withdrawn, the plasma levels of CBZ itself and of sodium valproate being within the 'therapeutic range'.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6440825     DOI: 10.1111/j.1469-8749.1984.tb08169.x

Source DB:  PubMed          Journal:  Dev Med Child Neurol        ISSN: 0012-1622            Impact factor:   5.449


  8 in total

Review 1.  Pharmacokinetic interactions between antiepileptic drugs. Clinical considerations.

Authors:  R Riva; F Albani; M Contin; A Baruzzi
Journal:  Clin Pharmacokinet       Date:  1996-12       Impact factor: 6.447

Review 2.  Therapeutic drug monitoring of anticonvulsants. State of the art.

Authors:  I A Choonara; A Rane
Journal:  Clin Pharmacokinet       Date:  1990-04       Impact factor: 6.447

Review 3.  Brivaracetam as adjunctive therapy for the treatment of partial-onset seizures in patients with epilepsy: the current evidence base.

Authors:  Christian Brandt; Theodor W May; Christian G Bien
Journal:  Ther Adv Neurol Disord       Date:  2016-09-01       Impact factor: 6.570

4.  Childhood Epilepsy : Current Therapeutic Recommendations.

Authors:  J T Gilman; M Duchowny
Journal:  CNS Drugs       Date:  1994-03       Impact factor: 5.749

5.  The use of transgenic cell lines for evaluating toxic metabolites of carbamazepine.

Authors:  C R Valentine; J L Valentine; J Seng; J Leakey; D Casciano
Journal:  Cell Biol Toxicol       Date:  1996-06       Impact factor: 6.691

Review 6.  Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine-10,11-epoxide. An update.

Authors:  L Bertilsson; T Tomson
Journal:  Clin Pharmacokinet       Date:  1986 May-Jun       Impact factor: 6.447

Review 7.  Formation of active metabolites of anticonvulsant drugs. A review of their pharmacokinetic and therapeutic significance.

Authors:  M J Eadie
Journal:  Clin Pharmacokinet       Date:  1991-07       Impact factor: 6.447

8.  Bioequivalence of oral and intravenous carbamazepine formulations in adult patients with epilepsy.

Authors:  Dwain Tolbert; James Cloyd; Victor Biton; Ihor Bekersky; Mark Walzer; David Wesche; Rebecca Drummond; Deborah Lee
Journal:  Epilepsia       Date:  2015-05-16       Impact factor: 5.864

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.